BridgeMD
New treatment option for Hypoparathyroidism Post-surgical
Official title Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism
ClinicalTrials.gov ID: NCT07034677
What this study is testing
What is Indapamide 1.5 MG SR?
Indapamide 1.5 MG SR is an investigational medicine, given as an once-weekly, being studied as a potential treatment for hypoparathyroidism post-surgical.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago
- Age ≥ 18 years
- Require treatment with active vitamin D ≥ 1 µg/day
- Ionized plasma calcium between 1.15-1.25 mmol/L
- 25(OH)D vitamin ≥ 50 nmol/L
You likely can't join if
- Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3
- Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago
- Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago
- Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg
- Plasma potassium \< 3.5 mmol/L
- Any current disease that might affect the calcium metabolism such as but not limited to:
See the full eligibility criteria
- Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago
- Age ≥ 18 years
- Require treatment with active vitamin D ≥ 1 µg/day
- Ionized plasma calcium between 1.15-1.25 mmol/L
- 25(OH)D vitamin ≥ 50 nmol/L
- Plasma magnesium \> 0.65 mmol/L
- Able to read and understand Danish
- Willing and able to sign the informed consent form
- Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3
- Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago
- Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago
- Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg
- Plasma potassium \< 3.5 mmol/L
- Any current disease that might affect the calcium metabolism such as but not limited to:
- Recent prolonged immobility
- Untreated diabetes (HbA1c \> 53 mmol/mol)
- Severe liver disease or hepatic encephalopathy
- Untreated thyroid disease
- Current disease that might affect gastrointestinal absorption
- Use of medications such as lithium or diuretics within 4 weeks prior to start of treatment
- Known allergy or sensitivity to Indapamide, its excipients or sulfonamides
- Known galactosemia, lactase deficiency, or glucose-galactose malabsorption
The study team makes the final eligibility decision.
Where it's taking place
- Aarhus, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarhus, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.